Cart
sales@molnova.com
Ticlopidine
CAS No. 55142-85-3
Ticlopidine( —— )
Catalog No. M17538 CAS No. 55142-85-3
Ticlopidine is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 30 | In Stock |
|
| 25MG | 61 | In Stock |
|
| 50MG | 90 | In Stock |
|
| 100MG | 137 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 343 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTiclopidine
-
NoteResearch use only, not for human use.
-
Brief DescriptionTiclopidine is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor.
-
DescriptionTiclopidine is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor.(In Vitro):Ticlopidine exhibits activity against human CD39 with apparent Ki,app values of 14 μM.Ticlopidine inhibits recombinant human CD39 expressed in COS-7-cells with the Ki value of 127±12 μM.Growth rate is affected during the first days of culture, Ticlopidine (30 and 150 μM) reducing its effect in the following days.(In Vivo):Oral administration of Losartan with 10 mg/kg Ticlopidine significantly increases the AUC (by 65.0%), suggesting that Ticlopidine can effectively inhibit the metabolism of losartan in the intestine and/or liver.
-
In VitroTiclopidine exhibits activity against human CD39 with apparent Ki,app values of 14 μM.Ticlopidine inhibits recombinant human CD39 expressed in COS-7-cells with the Ki value of 127±12?μM.Growth rate is affected during the first days of culture, Ticlopidine (30 and 150 μM) reducing its effect in the following days. Cell Proliferation Assay Cell Line:Human endothelial cells Concentration:30 and 150 μM Incubation Time:2, 6; 10 days Result:Treated cells grow slower if compared with controls and this effect correlates with the concentration of Ticlopidine in the culture medium.
-
In VivoOral administration of Losartan with 10 mg/kg Ticlopidine significantly increases the AUC (by 65.0%), suggesting that Ticlopidine can effectively inhibit the metabolism of losartan in the intestine and/or liver. Animal Model:Male Sprague-Dawley rats (7-8 weeks old, weighing 270-300 g)Dosage:4 or 10 mg/kg Administration:Orally administered 30 min before oral administration of losartan.Result:The AUC and Cmax of Losartan after oral administration with Losartan and 10 mg/kg Ticlopidine were significantly greater (by 65.0% and 49.4%, respectively) than those of control rats.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorADP
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number55142-85-3
-
Formula Weight263.78
-
Molecular FormulaC14H14ClNS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (379.09 mM)
-
SMILESC1CN(Cc2c1scc2)Cc1ccccc1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Maffrand, JP (2012). Comptes Rendus Chimie. 15 (8): 737–743.
molnova catalog
related products
-
AZD8931 diFuMaric ac...
AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth.
-
Mutated EGFR-IN-1
Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.
-
Olmutinib
Olmutinib is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorOlmutinib at 3 μM significantly reversed drug resistance mediated by ABCG2, but not by ABCB1 and ABCC1, by antagonizing the drug efflux function in ABCG2-overexpressing cells.?
